Juniper Pharma Services strengthens capsule capability with Xcelodose
![](/46/pdcnewsitem/03/80/52/juniper.jpg)
Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, has reinforced its early stage capsule filling expertise with the expansion of its Xcelodose powder micro-dosing system as part of its suite of GMP capabilities.
The move by the contract development and manufacturing organisation (CDMO) follows demand from its clients to develop the technique to complement its development services and help get new molecules to Phase I clinical trials quicker.
Xcelodose enables Juniper Pharma Services to accurately fill API directly into capsules in an efficient and automated manner to primarily support first-in-human studies, reduce formulation requirements and minimise drug substance wastage.
Claire Madden-Smith, senior VP at Juniper Pharma Services, said: “We have focused on having a broad range of development capabilities to enable our clients to rapidly access the most appropriate solution to meet their need. The increased usage of Xcelodose is a natural expansion of our manufacturing services.
“Encouragingly, the service is already helping satisfy the growing needs of our clients to get to clinical trials as quickly as possible without compromising on quality. The technique simply allows us to make and supply batches of the drug in capsules for clinic in a much more precise and economical manner.
“Given the shortage of CDMOs in the industry with the capability and expertise to offer Xcelodose in conjunction with associated development and analytical services, we expect a continuation of uptake of our enhanced offering.”
Xcelodose provides the automated processing of API directly into capsules at very low doses and is an ideal tool for highly soluble products and potent molecules. The use of the system removes the requirement for complex formulation development and allows companies to generate invaluable data on a compound in a cost effective way.
With an established track record of helping pharmaceutical companies and emerging biotechs develop new products and platforms, Juniper Pharma Services is able to optimise formulation performance through its science-led approach to projects.
The company has well-established GMP clinical manufacturing capabilities covering topical and oral dosage form products, including the supply of potent compounds and controlled drugs. Since 1997, the CDMO has built a strong reputation in materials characterisation, formulation analysis and IP consultancy.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance